Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial

LUX-Lung 5 Investigators

研究成果: Article同行評審

91 引文 斯高帕斯(Scopus)

指紋 深入研究「Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial」主題。共同形成了獨特的指紋。

Medicine & Life Sciences